73032-94-7 Usage
Description
Somatostatin 28, Cyclic is a peptide hormone that consists of 28 amino acids and is synthesized in the hypothalamus and other parts of the nervous system. It is a cyclic peptide with a disulfide bridge that connects two cysteine residues, forming a ring structure. This cyclic structure is crucial for its stability and biological activity. Somatostatin 28, Cyclic plays a vital role in regulating various physiological processes, including growth hormone secretion, insulin release, and gastrointestinal motility.
Uses
Used in Pharmaceutical Industry:
Somatostatin 28, Cyclic is used as a therapeutic agent for the treatment of various medical conditions, such as acromegaly, a disease characterized by excessive growth hormone secretion, and gastrointestinal disorders, including diarrhea and malabsorption syndromes. It works by inhibiting the release of growth hormone and insulin, as well as slowing down gastrointestinal motility, which helps in managing the symptoms of these conditions.
Used in Research Applications:
Somatostatin 28, Cyclic is used as a research tool to study the effects of somatostatin on various physiological processes. It has been used to investigate the role of somatostatin in regulating hepatic growth hormone sensitivity, providing insights into the mechanisms underlying the regulation of growth hormone secretion. Additionally, it has been employed to study its effects on insulin-like growth factor-I receptor expression in the gills of Oncorhynchus mykiss, a teleost fish, which can help in understanding the role of somatostatin in the growth and development of aquatic organisms.
Hazard
A poison.
Biochem/physiol Actions
Somatostatin plays an important role in regulating the metabolism of other hormones such as growth hormone, insulin, IGF-1 (insulin-like growth factor 1), glucagon, glucagon-like peptide and gastrin. Somatostatin has both regulatory and inhibitory functions. It retards gastrointestinal motility and gallbladder contraction, suppresses gut exocrine secretion and reduces epithelial proliferation. Somatostatin is associated with intestinal nutrient absorption and blood flow regulation. This peptide hormone is believed to inhibit cell proliferation and promote apoptosis. Somatostatin acts as a neurotransmitter and neuromodulator, and is also associated in maintaining water balance.
Check Digit Verification of cas no
The CAS Registry Mumber 73032-94-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,3,0,3 and 2 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 73032-94:
(7*7)+(6*3)+(5*0)+(4*3)+(3*2)+(2*9)+(1*4)=107
107 % 10 = 7
So 73032-94-7 is a valid CAS Registry Number.
InChI:InChI=1/C137H207N41O39S3/c1-69(154-113(194)82(37-19-22-47-138)159-115(196)85(40-25-50-149-136(145)146)160-118(199)87(44-45-106(188)189)163-116(197)86(41-26-51-150-137(147)148)164-130(211)101-43-27-52-177(101)133(214)72(4)156-114(195)88(46-54-218-7)158-110(191)71(3)155-129(210)100-42-28-53-178(100)134(215)95(61-104(144)186)171-126(207)96(65-180)172-124(205)93(59-102(142)184)165-111(192)70(2)153-112(193)80(141)64-179)109(190)152-63-105(187)157-98-67-219-220-68-99(135(216)217)174-127(208)97(66-181)173-132(213)108(74(6)183)176-125(206)91(57-77-33-15-10-16-34-77)170-131(212)107(73(5)182)175-119(200)84(39-21-24-49-140)161-122(203)92(58-78-62-151-81-36-18-17-35-79(78)81)168-121(202)90(56-76-31-13-9-14-32-76)166-120(201)89(55-75-29-11-8-12-30-75)167-123(204)94(60-103(143)185)169-117(198)83(162-128(98)209)38-20-23-48-139/h8-18,29-36,62,69-74,80,82-101,107-108,151,179-183H,19-28,37-61,63-68,138-141H2,1-7H3,(H2,142,184)(H2,143,185)(H2,144,186)(H,152,190)(H,153,193)(H,154,194)(H,155,210)(H,156,195)(H,157,187)(H,158,191)(
73032-94-7Relevant articles and documents
Pharmaceutical compositions containing growth-hormone inhibitors or their biologically active fragments for the treatment of uterine myomas
-
, (2008/06/13)
Pharmaceutical compositions containing growth-hormone inhibitors or their biologically active fragments for the treatment of uterine myomas are described.
